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Pathological hallmarks of amyotrophic lateral sclerosis (ALS), including protein
misfolding, are well established in oligodendrocytes. More recently, an RNA trafficking
deficit of key myelin proteins has been suggested in oligodendrocytes in ALS but
the extent to which this affects myelination and the relative contribution of this to
disease pathogenesis is unclear. ALS autopsy research findings showing demyelination
contrasts with the routine clinical-pathological workup of ALS cases where it is rare to
see white matter abnormalities other than simple Wallerian degeneration secondary to
widespread neuronal loss. To begin to address this apparent variance, we undertook
a comprehensive evaluation of myelination at an RNA, protein and structural level
using human pathological material from sporadic ALS patients, genetic ALS patients
(harboring C9orf72 mutation) and age- and sex-matched non-neurological controls. We
performed (i) quantitative spatial profiling of the mRNA transcript encoding myelin basic
protein (MBP), (ii) quantification of MBP protein and (iii) the first quantitative structural
assessment of myelination in ALS post-mortem specimens by electron microscopy.
We show no differences in MBP protein levels or ultrastructural myelination, despite
a significant dysregulation in the subcellular trafficking of MBP mRNA in ALS patients
compared to controls. We therefore confirm that whilst there are cell autonomous
mRNA trafficking deficits affecting oligodendrocytes in ALS, this has no effect on
myelin structure.
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INTRODUCTION
Oligodendrocyte pathology has been demonstrated in ALS post-
mortem tissue (Kang et al., 2013; Philips et al., 2013; Lorente
Pons et al., 2020); however, the relevance and/or contribution of
this pathology to disease pathogenesis is relatively understudied.
Oligodendrocytes provide support to neurons through two key
roles: myelination and metabolic support (Saab et al., 2013).
With regards to myelination, previous studies have shown
demyelination in ALS autopsy samples (Kang et al., 2013; Philips
et al., 2013). These findings are in contrast to what is seen
commonly in routine neuropathology practice, where it is rare to
observe demyelinating lesions in ALS patient material other than
Wallerian degeneration secondary to neuronal loss (Kang et al.,
2013). Furthermore, MRI imaging findings are most consistent
with white matter abnormalities that reflect neuronal loss and
axonal degeneration (Grolez et al., 2016; Martin et al., 2016;
Pallebage-Gamarallage et al., 2018; Querin et al., 2019), rather
than demyelination per se.
Myelin basic protein (MBP) is one of several proteins that is
translated locally in the terminal processes of oligodendrocytes
and is a major constituent in myelin. Local translation is
especially important in cells with multiple, often long processes,
making these cells reliant on adequate mRNA trafficking from the
cell body to the translation machinery at the terminal processes.
Errors in neuronal axonal transport, and more specifically mRNA
trafficking and stability, have been implicated in ALS through
cell, and potentially non-cell, autonomous mediated mechanisms
(Lin et al., 1998; Chang et al., 2008; Bilsland et al., 2010;
Swarup et al., 2011; Millecamps and Julien, 2013; Fallini et al.,
2016). Of relevance to impaired RNA homeostasis, over 95%
of ALS patients display pathological accumulation of TDP-
43, an RNA-binding protein that binds to 30% of the human
transcriptome (Neumann et al., 2006; Freibaum et al., 2010;
Ling et al., 2013). Indeed, dysregulated RNA metabolism is also
observed in ALS due to C9orf72 hexanucleotide repeat expansion
(Prudencio et al., 2015), the most common known genetic cause
of ALS. Disrupted RNA trafficking and metabolism has been
demonstrated in neurons in ALS and the relevance of these
findings to oligodendrocytes, which not only display the hallmark
pathologies of ALS as well as rely on local translation of many
RNAs involved in myelination and metabolism, is becoming
clearer through the examination of post-mortem patient samples
(Khalil et al., 2018; Lorente Pons et al., 2020). Indeed, many
known binding partners of TDP-43 have been implicated in
oligodendrocyte function. These include MBP mRNA that is
trafficked by heterogeneous nuclear ribonucleoproteins (hnRNP)
A2/B1 and A3 (Müller et al., 2013); hnRNP A2/B1 and hnRNP A3
are also sequestered by RNA foci transcribed from the GGGGCC
repeat (Kapeli et al., 2017). It has been hypothesized recently
that oligodendrocyte pathology may be contributing to ALS
pathogenesis through deficits in mRNA trafficking and that, in
some cases, these effects may exceed neuronal pathology (Lorente
Pons et al., 2020). We have also shown previously that up to
a fifth of ALS cases (sporadic and genetic) examined at post-
mortem have a purely glial pathological signature, with little if
any neuronal pathology in non-motor brain regions (Gregory
et al., 2019). These findings raise the possibility of a role for
cell autonomous glial pathology such as myelination deficit
due to disrupted MBP mRNA trafficking in both sporadic and
genetic ALS.
Against this background, we have undertaken a
comprehensive study of human pathological material with
a focus on MBP and myelination from sporadic ALS patients,
C9orf72 patients and age- and sex-matched non-neurological
controls. Specifically, we performed (i) quantitative spatial
profiling of the MBP mRNA transcript to understand subcellular
localization using a modified in situ hybridization technique
called BaseScopeTM, which allows for the identification
of single mRNA transcripts at single cell resolution, (ii) a
comprehensive quantification of MBP protein and (iii) a
quantitative structural assessment of myelination assessed




Human brain tissue was provided by the Medical Research
Council (MRC) Edinburgh Brain and Tissue Bank. Patients were
identified as having a diagnosis of ALS with further classification
as to whether the disease was sporadic or familial (with genetic
screening identifying the pathological mutation); patient details
are listed in Supplementary Table 1. Age-matched controls
were chosen from the Lothian Birth Cohort 1936 (LBC1936),
a cohort who have detailed cognitive assessment throughout
life, and were listed as negative for ALS diagnosis and TDP-
43 pathology. We used LBC1936 control subjects (n = 3–5;
control) ALS patients with sporadic disease (n = 3–5; sALS)
and ALS patients harboring a C9orf72 HRE (n = 3–5, C9 ALS).
All post-mortem tissue was collected via the Edinburgh Brain
Bank (ethics approval from East of Scotland Research Ethics
Service, 16/ES/0084) in line with the Human Tissue (Scotland)
Act. Use of human tissue for post-mortem studies has been
reviewed and approved by the Edinburgh Brain Bank ethics
committee and the Academic and Clinical Central Office for
Research and Development (ACCORD) medical research ethics
committee (AMREC).
At autopsy, brains were sectioned coronally and then regions
of interest from the right and left hemispheres were fixed in 10%
formalin, with complementary regions from the left hemisphere
snap frozen in liquid nitrogen. Separately, small blocks were
excised and fixed for electron microscopy. Formalin fixed blocks
underwent dehydration in ethanol titrations (70–100%), were put
through three xylene washes before being infiltrated with paraffin
wax. Blocks were then embedded in paraffin wax and sectioned
at 4 µm onto Superfrost slides. The region of interest used for
this study was the standardized Brodmann area (BA)4 allowing
analysis of the primary motor cortex white matter. For g-ratio
analysis, samples of anterior corpus callosum and subcortical
white matter (BA6/8) were processed for EM as previously
described (Kay et al., 2013). Briefly, tissue was dissected into small
blocks and fixed in 4% paraformaldehyde and 1% glutaraldehyde
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in 0.1 M PB for 48 h. Once fixed, the blocks were washed twice
in 0.1 M PB and then incubated in 1% osmium tetroxide for
30 min and then negatively stained with 1% uranyl acetate before
dehydration through titrations of ethanol and propylene oxide;
blocks were then embedded in Durcupan resin for 48 h at 56◦C.
Ultrathin sections (70 nm) were cut from selected areas, stained
in Uranyl Acetate and Lead Citrate then viewed in a JEOL JEM-
1400 Plus TEM. Two blocks were analyzed per patient (n = 3
patients per group) per region and images were taken using a
GATAN OneView camera. The white matter was identified as
regions with densely myelinated axons and all of our blocks were
entirely white matter enabling us to utilize the entire grid; we
commenced imaging in the top left corner of the grid and imaged
clockwise until at least 100 axons per patient were imaged. We
aimed for 150 countable analyzable axons per block and this
varied between 10 and 20 grids being imaged, depending on
the integrity of the tissue. G-ratios were calculated using Fiji




BaseScopeTM probes were designed and constructed by ACD for
three transcripts of interest: the oligodendrocyte specific mRNA
transcripts human myelin basic protein (MBP), human carbonic
anhydrase II (CAII), as well as C9 RNA foci (BA-GGGGCCn-3zz-
st; ACD #704181). Both the MBP and CAII probes were designed
to amplify all transcript variants for both genes to allow extensive
coverage of expression.
For all probes, BaseScopeTM RED Reagent Kits were used
and assays were run according to guidelines provided. Briefly,
sections were dewaxed and rehydrated, blocked for endogenous
peroxidases and then antigen retrieval was carried out using the
ACD pre-treatment reagent. Protease III was used (30 min; 40◦C)
before incubation with the probe (2 h; 40◦C). Slides probed with
the C9 RNA foci probe (Supplementary Data) were treated with
800 U/ml DNase (30 min; RT) after Protease III but prior to probe
incubation, as published previously (Mehta et al., 2020). Each
Amp reagent was used as per kit instructions; incubations at 40◦C
were conducted using the HybEZ II Oven (ACD). Following final
amplification with Fast Red (Fast Red incubation time was 10 min
for MBP and CAII probes and 2 min for C9 probe), slides were
counterstained in hematoxylin and then left to dry prior to being
cleared in xylene and cover-slipped.
Two sections of motor cortex were used per patient (one
from each hemisphere) with analyses limited to the white matter.
Slides were scanned using a Nanozoomer (Hamamatsu) and ten
fields of view were taken per section at 20x magnification using
NDP.view 2 imaging software (Hamamatsu) and analyzed in Fiji
(ImageJ). The MBP mRNA was quantified in three ways: (1)
the density of nuclei with 7 or more transcripts were counted
(nuclear expression should be low because MBP is trafficked
for local translation); (2) the density of nuclear aggregations of
MBP transcripts whereby more than half the nucleus is occupied
by transcripts; and (3) density of cytoplasmic aggregations of
MBP transcripts whereby 5 or more transcripts were clustered
together in the perinuclear space. CAII mRNA counts were
ranked based on a scoring system whereby 0 = no aggregates,
1 = one aggregate, 2 = between one and five aggregates and




For histological staining, sections were de-waxed and rehydrated
prior to staining in Luxol Fast Blue overnight at 40◦C. The
stain was differentiated in 0.1% lithium carbonate prior to
dehydration, clearing and coverslipping. For immunostaining
(Supplementary Data), the Novolink Polymer detection
system was used to stain for phospho-TDP-43 (s409-410)
(Cosmo #TIP-PTD-M01; 1:4,000) and p62 (BD Biosciences
#610833; 1:2,000). Following DAB chromagen, the sections
were counterstained with hematoxylin. Slides were scanned
using a Nanozoomer (Hamamatsu) and representative images
extracted using NDP.view 2 (Hamamatsu). Assessors were
blinded to all demographic and clinical information. For
immunostaining of the dipeptide repeat proteins (DPRs) GA
(Everest Biotech G2 CUST05049; 1:200) and GP (Everest
Biotech G2 CUST05048; 1:100), sections were manually stained
without the Novolink system but still with DAB chromagen
and hematoxylin counterstain. We were only able to optimize
antibodies for these two DPRs in our tissue. Glial identification
was based on a well-established morphological criteria and
carried out by a trained neuropathologist.
Human Post-mortem
Tissue—Biochemical Analysis
From frozen blocks of motor cortex, white matter was dissected
and used for RNA and protein extraction. The samples
were homogenized in their respective buffers for RNA or
protein isolation.
For RNA extraction, the RNeasy lipid tissue mini
kit (Qiagen) was used according to the guidelines
provided. RNA concentration was measured using a
spectrophotometer (DeNovex) and cDNA synthesized for
quantitative real time PCR (qPCR). The gene of interest
was MBP (F: 5′-CTTCTTTGGCGGTGACAGG-3′, R: 5′-
CGGGGTTTTCATCTTGGGTC-3′) and housekeepers 18S
(F: 5′-GTAACCCGTTGAACCCCATT-3′, R: 5′-CCATCCAAT
CGGTAGTAGCG-3′) and β-actin (F: 5′-GTTACAGGAAG
TCCCTTGCCATCC-3′, R: 5′-CACCTCCCCTGTGTGGACT
TGGG-3′) were used for normalization. The MBP primers
were designed to span exon 2 and 3 of the transcript
variants that encode the 18.5 kDa protein isoform; this
is the most abundant protein that is translated locally in
oligodendrocytes. Gene expression of CAII was also measured
using qPCR (F: 5′-TGGTCATGCTTTCAACGTGG-3′, R:
5′-CCATCAAGTGAACCCCAGTG). The method of analysis
employed for the qPCR data was the 11CT method.
For protein extraction, tissue was homogenized in RIPA buffer
(50 mM Tris HCl pH 7.4, 0.1% SDS, 0.5% sodium dioxycholate,
1% Triton-X, 150 mM NaCl, 2 mM EDTA, protease inhibitor,
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FIGURE 1 | RNA trafficking of myelin basic protein (MBP) is dysregulated in oligodendrocytes. MBP mRNA transcript localization is altered in sporadic ALS (sALS)
patients and ALS patients with a C9orf72 mutation (C9 ALS) compared to controls. (A) Graph demonstrating number of oligodendrocytes (OLs) with 7 or more
nuclear MBP transcripts. Data show that C9orf72 ALS cases had a higher proportion of nuclei with > 7 transcripts (p < 0.05 compared to control; n = 4–5 cases for
each genotype). (B) Graph demonstrating number of oligodendrocytes (OLs) with aggregations of MBP transcripts. Data show that C9orf72 cases have more
nuclear aggregations of MBP transcripts (p < 0.05 compared to control; n = 4–5 cases for each genotype). (C) Graph demonstrating number of cytoplasmic
aggregations of MBP transcripts. Some sALS and C9orf72 cases have more cytoplasmic aggregations than control individuals (n = 4–5 cases for each genotype).
(D) Representative image from a control case showing MBP positive transcripts within the cytoplasm and cellular processes. (E) Representative image of a sALS
case showing prominent cytoplasmic aggregates of transcripts. (F) Representative image from a C9orf72 case demonstrating prominent nuclear and cytoplasmic
aggregations of transcripts. * denotes p < 0.05. Scale bar = 50 µm.
phosphatase inhibitor). Samples were incubated on ice and then
centrifuged at 15,700 × g for 5 min at 4◦C; the supernatant
was transferred to a fresh Eppendorf. Protein concentration
was assessed by a BCA protein assay (Pierce), then Laemmli
buffer was added (125 mM Tris HCl pH 6.8, 4% SDS, 4%
β-mercaptoethanol, 20% glycerol and 0.004% bromophenol blue)
and samples were boiled for 10 min at 99◦C. For the western
blots, protein (20 µg for SOX-10 and 1 µg for MBP) was run
on 4–20% SDS/Poly acrylamide gel electrophoresis (Invitrogen)
for 2.25 h at 90 V and blotted onto a 0.45 µm polyvinylidene
fluoride membrane at 20 V with a transfer time of 1 h 20 min.
Membranes were blocked in 5% milk in TBS-T and probed
with either MBP (1:1,000; #05-675 Merck) or SOX10 (1:2,500;
Ab155279 Abcam) (and β-actin as a housekeeping protein
(1:10,000; #A2228 Sigma Aldrich)) overnight at 4◦C, appropriate
horse radish peroxidase-tagged secondary antibodies (1:5,000;
Dako) at room temperature for 2 h and then developed using ECL
(GE Healthcare). Blots were scanned and densitometry analysis
performed using Fiji (Image-J). Full lane representations are
included (see Supplementary Figure 5).
Frontiers in Neuroscience | www.frontiersin.org 4 September 2021 | Volume 15 | Article 705306
fnins-15-705306 August 26, 2021 Time: 12:25 # 5
Barton et al. Oligodendrocytes in Amyotrophic Lateral Sclerosis
FIGURE 2 | MBP mRNA and protein levels were variable and not relative to
RNA trafficking dysfunction. (A) Graph showing MBP gene expression in
whole tissue homogenate of motor cortex white matter showing no
statistically significant difference in expression between cases (n = 3 for each
genotype). (B) Graph showing SOX10 and protein expression of two MBP
protein isoforms in whole tissue homogenate of motor cortex white matter
showing variable but not significantly different protein expression between
cases (n = 3 for each genotype). (C) Western blot that was graphed in b
showing SOX10 and MBP protein expression.
Statistical Analyses
Data are presented as mean ± SEM. All outputs were analyzed
using a one-way ANOVA and Dunnett’s multiple comparisons
test for post hoc comparisons comparing sALS and C9 ALS
groups to control. ∗ indicates p < 0.05.
RESULTS
Oligodendrocytes in the Motor Cortex
White Matter of Patients With ALS
Display MBP RNA Trafficking Deficits
Given recent findings suggesting protein pathology in
oligodendrocytes in ALS is associated with an RNA trafficking
deficit (Lorente Pons et al., 2020), we first evaluated hallmark
protein pathologies in oligodendrocytes. In support of previous
findings (Neumann et al., 2006; Lorente Pons et al., 2020), we
identified TDP-43 and p62 pathology in both sporadic and
C9orf72 patients (Supplementary Figure 1) as well as C9orf72
specific pathologies including RNA foci and dipeptide repeat
protein accumulation (GP and GA; Supplementary Figure 2).
To assess RNA trafficking, we measured expression of MBP
mRNA, encoding one of the most abundant myelin proteins
and a trafficked mRNA for local translation, using BaseScopeTM.
Qualitative assessment of the distribution of the oligodendrocyte
specific mRNA transcript MBP in control samples showed evenly
dispersed MBP mRNA localized to the neuropil consistent with
localization within cellular process implying adequate mRNA
transport to terminal processes (Figure 1A). In contrast, samples
from sALS (Figure 1B) and C9orf72 patients (Figure 1C),
revealed MBP mRNA accumulation in mRNA inclusions in both
the nucleus and cellular processes. Quantification showed an
increased number of oligodendrocytes with seven or more MBP
mRNA transcripts in C9orf72 ALS patients compared to controls
(p = 0.043; Figure 1D) as well as an overall increase in the
number of oligodendrocytes with aggregations of MBP mRNAs
(whereby more than half the nucleus was occupied by MBP
transcripts; Figure 1E) compared to controls (p = 0.013). Finally,
perinuclear aggregates of MBP transcripts (whereby 5 or more
MBP transcripts were clustered together) were present in sALS
and C9orf72 ALS cases but the variability amongst cases meant
this did not reach statistical significance (p = 0.19; Figure 1F).
To determine if the RNA trafficking deficit was specific to
MBP or affected other oligodendrocyte-specific mRNAs not
involved in myelin production as previously reported (Lorente
Pons et al., 2020) we next examined the distribution of CAII.
CAII expression is abundantly expressed in oligodendrocytes
(Komoly et al., 1987; Lorente Pons et al., 2020) and is a
known binding partner of monocarboxylate transporter 1
(MCT1), the oligodendrocyte lactate transporter. A higher
proportion of sALS (Supplementary Figure 3B) and C9orf72
ALS (Supplementary Figure 3C) cases had aggregations
of CAII mRNA transcripts compared to control cases
(Supplementary Figure 3A) but this did not reach statistical
significance (p = 0.17; Supplementary Figure 3D). There was also
no statistical difference in total CAII gene expression between
groups as measured using qPCR (Supplementary Figure 4).
MBP mRNA Aggregation Does Not Affect
Myelination
Having established disruption of MBP mRNA trafficking in
C9orf72 and sALS cases, we next wanted to ascertain whether
this had an effect on the total amount of MBP mRNA and
protein. We used qPCR to measure abundance of MBP mRNA,
with primers designed to amplify the splice variant commonly
trafficked for local translation, and found variable expression in
ALS cases but no statistically significant difference (Figure 2A).
This variability was also apparent with respect to total MBP
protein levels when assessing both the 18.5 and 21.5 kDa isoforms
(Figures 2B,C).
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FIGURE 3 | Myelin thickness is not altered in ALS patients. (A) Graph showing the g-ratio calculated for sALS and C9orf72 ALS patients and compared to control
patients in the BA6/8 subcortical white matter showing no difference between cases; n = 3 for each genotype. (B) Graph showing the g-ratios for each individual
sALS and C9orf72 ALS patient compared to controls in the BA6/8 subcortical white matter. (C) Graph showing g-ratio respective to axon diameter for control
patients (black), sALS patients (blue) and C9orf72 patients (red) in the BA6/8 subcortical white matter. (D) Representative electron micrograph from the motor cortex
white matter of a C9 ALS patient. (E) Graph showing the g-ratio calculated for sALS and C9orf72 ALS patients and compared to control patients in the corpus
callosum showing no difference between cases; n = 3 for each genotype. (F) Graph showing the g-ratios for each individual sALS and C9orf72 ALS patient
compared to controls in the corpus callosum. (G) Graph showing g-ratio respective to axon diameter for control patients (black), sALS patients (blue) and C9orf72
patients (red) in the corpus callosum. (H) Representative electron micrograph from corpus callosum of a C9 ALS patient Scale bar = 7 µm.
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FIGURE 4 | There is no difference in myelin density between groups. (A–C) Representative images of Luxol Fast Blue histological staining of the motor cortex (BA4)
showing no difference in staining intensity between groups. (D) Graph showing no difference in the optical density in sALS and C9 ALS patients compared to
controls. Optical density was calculated by measuring the average intensity of staining of the entire white matter region per section; a higher optical density
correlates to worse myelination.
To more comprehensively assess myelination, we next
undertook luxol fast blue (LFB) tinctorial staining of the motor
cortex white matter as well as electron microscopy (EM) of both
the motor cortex and corpus callosum of ALS patient human
post-mortem tissue compared to age- and sex- matched controls.
No difference was found in the ultrastructural evaluation of
myelination using gold standard g-ratio measurements in either
the subcortical white matter adjacent to the motor cortex
(Figures 3A–D) nor the corpus callosum (Figures 3E–H). This
was further confirmed using LFB staining (Figures 4A–D).
Whilst our findings don’t rule out altered nodal morphology nor
the presence of myelin blebbing, our findings show that there
is no structural change in the compaction of myelination in the
cortex of ALS patients, despite MBP disrupted mRNA trafficking.
DISCUSSION
RNA trafficking is disrupted in motor neurons in ALS and this
has been attributed to common ALS pathologies, including
TDP-43 aggregation, resulting in microtubule instability,
axonal transport defects and impaired synaptic activity
(Khalil et al., 2018; Lorente Pons et al., 2020). It is well
established that many mRNAs are also locally translated in
oligodendrocytes and oligodendrocytes harbor common ALS
pathologies, yet there has been limited study of RNA trafficking
in oligodendrocytes in ALS. Here, our data suggests disrupted
RNA trafficking in oligodendrocytes in both sporadic ALS cases
and C9orf72 ALS cases.
Using BaseScopeTM, we undertook qualitative (spatial and
subcellular localization) and quantitative examination of RNA
trafficking in oligodendrocytes in ALS. ALS patient samples
exhibited pathological accumulation of mRNAs both within
the nucleus and in the oligodendrocyte processes/cytoplasm,
with the patterns of accumulation mirroring the pattern of
proteinopathy observed in both sALS and C9orf72 cases
(Supplementary Figures 1, 2). The C9orf72 and sALS cases
had increased nuclear localization of MBP mRNA and exhibited
cytoplasmic aggregations of MBP mRNA implying both impaired
nucleocytoplasmic transport as well as disrupted mRNA
trafficking. Indeed, the concept of impaired trafficking of MBP
mRNA in oligodendrocytes in ALS has been suggested recently,
based on proportions of myelin protein expression (Lorente Pons
et al., 2020) and our use of the highly sensitive BaseScopeTM
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technique allowed us to spatially verify this at an mRNA level.
Further, it was suggested that the disruption to RNA trafficking
correlated to protein pathology (Lorente Pons et al., 2020),
an observation consistent with the pattern of MBP mRNA
accumulation in both sALS and C9orf72 ALS cases.
Impaired RNA trafficking was not limited to only MBP. We
also identified a trend toward impaired CAII mRNA trafficking in
sALS and C9orf72 ALS patients compared to controls. Although,
of itself, insufficient to make any firm conclusions it is of
particular interest given that CAII plays an important role
in the metabolic function of oligodendrocytes as a binding
partner for MCT1 (32). MCT1 is a key transporter responsible
for shuttling lactate out of oligodendrocytes to neurons and
has previously been reported to be reduced in ALS patients
(Lee et al., 2012; Philips et al., 2013). CAII is abundantly
expressed in oligodendrocytes (Komoly et al., 1987), locally
translated (Baron and Hoekstra, 2010) and is a binding partner of
hnRNP A2 (Carson and Barbarese, 2005). Together these finding
suggest a cell autonomous deficit of oligodendrocytes in ALS
and would argue for further studies, including examination of
metabolic dysfunction.
However, despite evidence of impaired mRNA trafficking,
no difference in myelination between control, sALS or C9orf72
cases was identified. Conflicting reports of myelination status
in ALS have been reported. Whilst one report showed a
significant decrease in MBP and CNPase protein levels in both
the human motor cortex and lumbar spinal cord gray matter
(Kang et al., 2013), another study conversely showed an increase
in CNPase protein levels (Lee et al., 2012). A more recent
study mirrored our findings by also showing no change to
MBP protein levels (Lorente Pons et al., 2020) suggesting a
compensatory mechanism within the oligodendrocytes allowing
them to maintain myelination despite impaired RNA trafficking.
In the well characterized SOD1G93A mouse model of ALS, one
study found decreased numbers of mature oligodendrocytes,
increased oligodendrocyte precursors as well as lower MBP and
CNPase protein levels yet also showed a lower g-ratio (which
corresponds to thicker myelin sheaths) and no quantifiable
difference in LFB staining of the lumbar spinal cord (Kang et al.,
2013). Another study in this same mouse model showed neither
a change to the number of mature oligodendrocytes, nor to MAG
and CNPase protein levels, but showed a decrease in MBP protein
at end stage disease (Philips et al., 2013). Crucially, these studies
did not evaluate patient post-mortem tissue from SOD1 patients
(spinal cord tissue may be especially informative), to assess the
translational relevance of these in vivo findings, highlighting
areas for future research.
Whilst we definitively show altered oligodendrocyte biology
in ALS, there are some limitations to our study that deserve
addressing. Access to, and ethical use of, human post-mortem
tissue limited our sample size yet we were still able to achieve
statistical power in our analyses. We predict that increasing
our sample size would indeed strengthen findings with respect
to altered RNA trafficking, given how stark the differences
were between sALS and C9 ALS cases compared to control.
Despite the small sample size, a strength of our study is
that we have used deeply phenotyped cases that has allowed
us to separate C9 ALS cases from sALS, which is important
when assessing cellular biology given their distinct pathologies
(particularly with respect to cellular localization of pathology)
despite converging on similar disease phenotypes, like impaired
RNA trafficking. We unfortunately were unable to co-label
such pathologies with oligodendrocyte-specific markers. When
assessing myelin biology using ALS patient post-mortem tissue,
two studies have assessed the 18.5 kDa MBP isoform with one
also assessing CNP levels (Kang et al., 2013) and the other
also assessing PLP levels (Lorente Pons et al., 2020). We chose
to only assess MBP as it is the only major myelin protein
known to be locally translated; we have assessed two MBP
isoforms, one that is locally translated and one that is not;
unfortunately, it remains challenging to further clarify other MBP
isoforms in human post-mortem tissue using standard Western
blotting. Whilst previous studies focusing on oligodendrocytes
have analyzed the lumbar spinal cord, we chose to focus
on the motor cortex white matter where an oligodendrocyte
deficit may be cell autonomous rather than secondary to
Wallerian degeneration.
CONCLUSION
Our findings, including the first ultrastructural examination
of human myelination in ALS, suggest that there is no
evidence of a myelination deficit in the motor cortex of
ALS patients. Despite no evidence of abnormal myelination,
oligodendrocytes have multiple other roles, many of which
depend on local translation, thereby highlighting that a cell
autonomous RNA trafficking deficit in oligodendrocytes may
still have significant functional consequences. In fact, previous
studies assessing Cnp1 loss of function in mice (33) demonstrated
an uncoupling of myelination and axonal support roles, where
molecules essential for axonal survival are not required for
myelin assembly, implying that these functions are distinct
and not interdependent. Consistent with this, we show that
although trafficking of MBP is disrupted in in sALS and
C9orf72 ALS cases, there is no evidence of an ultrastructural
deficit in myelination.
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